Lots of new things happened in the pharmaceutical industry in 2017. At IgeaHub.com, our mission is to make the pharmaceutical…

Lots of new things happened in the pharmaceutical industry in 2017. At IgeaHub.com, our mission is to make the pharmaceutical…
Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 Ariel3 Maintenance Treatment Trial of Rucaparib In Advanced Ovarian Cancer at…
Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 Ariel3 Maintenance Treatment Trial of Rucaparib In Advanced Ovarian Cancer Sep.…
Many new medications and treatments have emerged this year for improving the management and prognoses of patients suffering from serious…
APR 03, 2017 Novartis has announced the European Commission has approved Tafinlar®(dabrafenib) in combination with Mekinist® (trametinib) for treating patients with…
28 March 2017 Roche has announced the CE-IVD launch of cobas® HPV for use on the cobas® 6800/8800 Systems for…
March 23, 2017 The biopharma partners Merck KGaA and Pfizer came away with their first FDA approval of the…
March 14, 2017 Merck has received another FDA approval for Keytruda, and this time for classical Hodgkin lymphoma, marking the PD-1…
March 6, 2017 The FDA has given Seattle Genetics the green light to continue the trials for its armed antibody dubbed SGN-CD33A…
March 13, 2017 Novartis has gained the FDA approval for LEE011, its CDK 4/6 drug now approved as a frontline therapy…
March 2, 2017 Roche, Breast European Adjuvant Study Team (BrEAST), the Breast International Group (BIG) and Frontier Science Foundation (FS)…
February 28, 2017 EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. have announced that the…
February 23, 2017 Incyte Corporation has signed off on a multi-year deal for collaborating with scientists at the University of…
21 February 2017 Roche has announced that the European Commission has granted a conditional marketing authorisation for Alecensa® (alectinib) as…
17 February 2017 AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to…
Feb 7, 2017 Cellectis, the Paris-based biotech, has received an Investigational New Drug, or IND, approval from the U.S. Food and Drug…
17 January 2017 AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development program in 1st-line non-small cell…
January 25, 2017 Eisai says that its cancer drug Lenvima (lenvatinib) hit the primary endpoint in a Phase III study for the…
December 21, 2016 Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small…
With the increasing prevalence of different health conditions requiring expensive lifelong treatment, the global sales of therapeutics have been expected…